Deltex Medical Group plc (LON:DEMG) Chief Executive Officer Ewan Phillips caught up with DirectorsTalk for an exclusive interview to discuss their interim results for the six months ended 30 June..
Centralnic Group PLC (LON:CNIC) is the topic of conversation when Zeus Capital Research Analyst John Wilson caught up with DirectorsTalk for an exclusive interview Q1: Centralnic released their interims..
Oxford Biomedica plc (LON:OXB) is a specialist advanced therapy viral-vector biopharmaceutical company. It offers vector manufacturing and development services, whilst retaining proprietary drug candidates. OXB will also receive royalties on..
Diurnal Group Plc (LON:DNL) is a clinical stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead candidates are targeted at rare diseases with unmet medical..
Epwin Group Plc (LON:EPWN) are the topic of conversation when Andy Hanson, Director of Equity Research joins DirectorsTalk. Andy shares his thoughts on the latest interim results, explains what has..
Oncimmune Holdings plc (LON:ONC), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, today provided the following update on the business ahead of the announcement..
Gresham House plc (LON:GHE) announced today interim results for the 6 months ending 30 June 2017. 50% INCREASE IN ASSETS UNDER MANAGEMENT RESULTS IN ACCELERATION OF PROFITABILTY EXPECTATIONS · Continued..
Warpaint London PLC (LON: W7L), the specialist supplier of colour cosmetics and owner of the W7 brand, has today announced its unaudited interim results for the six months ended 30..
Advanced Oncotherapy plc (LON:AVO) Chief Operating Officer Ed Lee talks to DirectorsTalk about his background, what that experience brings to AVO and how that knowledge can translate into shareholder value...
